Stock Split Approved: Pharma Stock Declares 53.4% Jump In Net Profit, Record Date To Be Intimated

Small cap pharmaceuticals sector company Jagsonpal Pharmaceuticals Ltd on October 23 declared a jump of 53.41% in its net profit to Rs 11.46 crore for the quarter ended September 30, 2024 as compared to Rs 7.47 crore declared in the corresponding quarter of last year. The company also considered and approved stock split/sub-division of shares. Its sales surged 29.15% to Rs 74.69 crore for the quarter ended September 2024 as compared to Rs 57.83 crore reported in the similar quarter of last year. Last trading price of Jagsonpal Pharmaceuticals shares on BSE is Rs 478.90 per share with intraday gain of 1.60%. The company has a market capitalisation of Rs 1268.35 crore. Check details below:

Jagsonpal Pharmaceuticals Approves Stock Split/Sub-Division of Shares: As per the exchange filing of Jagsonpal Pharmaceuticals dated October 23, 2024, "Sub-division/ split of the existing Equity Shares of the Company, such that each Equity Share having face value of Rs. 5/- (Rupees Five only) each fully paid-up, be sub-divided/split into such number of Equity Shares having face value of Rs. 2 each fully paid-up, subject to the approval of Equity Shareholders of the Company through Postal Ballot."

The Record Date for sub-division/split of existing Equity Shares shall be decided after taking aforesaid approval of the Equity Shareholders of the Company. The Company will shortly be seeking approval of equity shareholders through postal ballot for the Sub-division/Split of shares and for consequent amendment to the Memorandum of Association/ Articles of Association of the Company.

Jagsonpal Pharmaceuticals Shares Performance: The 52-week high price of Jagsonpal Pharmaceuticals shares on BSE is Rs 499.80 per share (as on 24/10/2024) and 52-week low price is Rs 270.05 per share (as on 14/03/2024). Jagsonpal Pharmaceuticals shares jumped 1920% in last 5-years, rose 201% in last 3-years, and gained 18% in last 1-year. In last 6-months, Jagsonpal Pharmaceuticals shares zoomed 49%.

Disclaimer: The stock highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.